Loading...
XSHE
002007
Market cap3.45bUSD
Jul 10, Last price  
12.80CNY
1D
1.35%
1Q
-14.15%
Jan 2017
-64.20%
IPO
-34.53%
Name

Hualan Biological Engineering Inc

Chart & Performance

D1W1MN
XSHE:002007 chart
P/E
24.85
P/S
5.11
EPS
0.52
Div Yield, %
5.47%
Shrs. gr., 5y
0.06%
Rev. gr., 5y
-1.85%
Revenues
4.58b
+4.49%
352,991,929351,137,848475,162,7981,220,493,4291,261,620,656961,395,932972,460,2141,117,611,9981,243,487,9601,471,763,3081,934,669,6622,368,176,5683,216,898,7213,699,941,9895,023,206,2624,436,200,1254,516,979,4075,341,872,5564,379,196,6204,575,883,532
Net income
940m
-13.55%
79,001,163120,429,390187,258,195608,475,487612,360,499370,719,279299,787,876475,337,500538,417,400589,118,931780,312,525820,823,4751,139,512,9401,283,449,0541,613,105,2641,298,897,1671,076,265,2901,481,578,8561,087,850,986940,400,665
CFO
1.14b
+7.80%
131,429,335179,015,279161,175,908607,725,451609,531,570335,928,539494,692,263510,700,233497,148,698548,622,932329,938,357177,417,5221,292,636,1431,362,760,2811,325,292,9791,432,495,972957,311,9071,345,838,7811,059,345,1611,141,970,524
Dividend
Oct 27, 20250.5 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Hualan Biological Engineering Inc. operates as a biopharmaceutical company, specializing in the research, development, production, and commercialization of a diverse portfolio of medical products within the People's Republic of China. Its offerings span plasma-derived therapies, various viral and bacterial vaccines, recombinant proteins, and other advanced biologics. The company's extensive range of plasma products includes essential components like human albumin, a broad spectrum of human immunoglobulins (such as intravenous, rabies, hepatitis B, and tetanus formulations), and vital coagulation factors like human prothrombin complex and factor VIII. Hualan also provides specialized solutions such as lyophilized human thrombin for external use and surgical fibrin glue. In its vaccine division, Hualan offers critical immunizations, including several influenza vaccines (e.g., split virus, A H1N1, and quadrivalent forms), recombinant hepatitis B vaccine, and ACYW135 meningococcal polysaccharide vaccine. The company actively pursues strategic collaborations with key scientific organizations, most notably the Chinese Academy of Sciences, as well as other esteemed research institutes and enterprises. Established in 1992, Hualan Biological Engineering Inc. is headquartered in Xinxiang, People's Republic of China.
IPO date
Jun 25, 2004
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT